Acquiring Company
Valerio Therapeutics S.A
Acquired Company
eTheRNA
Paris
AntwerpenBiotechnologyHealth CareTherapeuticsManufacturingBiotechnologyTherapeuticsDescription
Valerio Therapeutics has signed a binding offer to acquire 100% of Etherna Immunotherapies' share capital. This acquisition aims to create a global leader in targeted RNA medicines. By combining their technologies, they will enhance the development and delivery of RNA therapeutics. The acquisition supports Valerio's strategy to advance their proprietary pipeline and manufacturing capabilities.
Quick answer
Valerio Therapeutics S.A is acquiring eTheRNA, announced July 1, 2026. Valerio Therapeutics S.A is based in Paris, Ile-de-France, France.
- How much did Valerio Therapeutics S.A pay for eTheRNA?
- The deal value was not disclosed.
- What does Valerio Therapeutics S.A do?
- Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) is a clinical-stage biotechnology company leading the way in the development of innovative DNA Decoy therapeutics.
- Where are Valerio Therapeutics S.A and eTheRNA based?
- Valerio Therapeutics S.A is based in Paris, Ile-de-France, France. eTheRNA is based in Antwerpen, Antwerp, Belgium.
- Who are the decision-makers at Valerio Therapeutics S.A?
- Fundz holds 5 contacts at Valerio Therapeutics S.A. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Jazz Pharmaceuticals acquires Actio Biosciences (August 10, 2026)
- Tarsus Pharmaceuticals to acquire Alkeus Pharmaceuticals (August 6, 2026)
- Bristol-Myers acquires Medarex for cancer pipeline (August 2, 2026)
- Tarsus acquires iRenix Medical for IRX-101 development (July 8, 2026)
- Gilead Sciences to acquire MacroGenics for $1.7B, $1.7B (May 19, 2026)
- Lakefront Biotherapeutics acquires Ouro Medicines (August 10, 2026)
Who to call at Valerio Therapeutics S.A, and when
When Valerio Therapeutics S.A changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Valerio Therapeutics S.A raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Valerio Therapeutics S.A, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Valerio Therapeutics S.A. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Valerio Therapeutics S.A makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired eTheRNA?
eTheRNA was acquired by Valerio Therapeutics S.A, based in Paris. The deal was reported on July 1, 2026. Valerio Therapeutics S.A. (Euronext Growth Paris: ALVIO) is a clinical-stage biotechnology company leading the way in the development of innovative DNA Decoy therapeutics. Valerio Therapeutics S.A is privately held and operates in Biotechnology.
When did Valerio Therapeutics S.A acquire eTheRNA?
Valerio Therapeutics S.A's acquisition of eTheRNA was reported on July 1, 2026. Valerio Therapeutics has signed a binding offer to acquire 100% of Etherna Immunotherapies' share capital. This acquisition aims to create a global leader in targeted RNA medicines. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does eTheRNA do?
It is privately held, operating in Manufacturing, and is based in Antwerpen.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.